Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2012	Mar. 27, 2013	Jun. 30, 2012
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Trading Symbol	GALT
Entity Registrant Name	GALECTIN THERAPEUTICS INC
Entity Central Index Key	0001133416
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,109,090
Entity Public Float			$ 29,900,000

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 9,364	$ 6,397
Prepaid expenses and other current assets	153	104
Total current assets	9,517	6,501
Property and equipment, net	8	6
Restricted cash and security deposit	6	69
Intangible assets, net	30	36
Total assets	9,561	6,612
Current liabilities:
Accounts payable	397	384
Accrued expenses	1,161	1,551
Accrued dividends payable	80	80
Deferred income		200
Total current liabilities	1,638	2,215
Other long-term liabilities	6
Total liabilities	1,644	2,215
Commitments and contingencies (Note 11)
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2012 and 2011, 8,001,000 shares designated at December 31, 2012 and 2011
Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,562,500 issued and outstanding at December 31, 2012 and 2011	632	632
Common stock, $0.001 par value; 50,000,000 shares authorized at December 31, 2012 and 2011, 16,060,853 and 12,919,538 issued and outstanding at December 31, 2012 and 2011, respectively	16	13
Additional paid-in capital	80,535	66,367
Deficit accumulated during the development stage	(80,018)	(69,137)
Total stockholders' equity (deficit)	1,165	(2,125)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	9,561	6,612
Series B-1 12% Redeemable Convertible Preferred Stock
Current liabilities:
Convertible preferred stock, value	1,698	1,681
Series B-2 12% Redeemable Convertible Preferred Stock
Current liabilities:
Convertible preferred stock, value	2,900	2,687
Series C Super Dividend Convertible Preferred Stock
Current liabilities:
Convertible preferred stock, value	$ 2,154	$ 2,154

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Undesignated stock, par value	$ 0.01	$ 0.01
Undesignated stock, shares authorized	20,000,000	20,000,000
Undesignated stock, shares designated	8,001,000	8,001,000
Series A 12% convertible preferred stock, shares authorized	5,000,000	5,000,000
Series A 12% convertible preferred stock, issued	1,562,500	1,562,500
Series A 12% convertible preferred stock, outstanding	1,562,500	1,562,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, issued	16,060,853	12,919,538
Common stock, outstanding	16,060,853	12,919,538
Series B-1 12% Redeemable Convertible Preferred Stock
Convertible preferred stock, shares authorized	900,000	900,000
Convertible preferred stock, issued	900,000	900,000
Convertible preferred stock, outstanding	900,000	900,000
Convertible preferred stock, redemption value	$ 1,800,000
Convertible preferred stock, liquidation value	1,800,000
Undesignated stock, shares designated	900,000
Series B-2 12% Redeemable Convertible Preferred Stock
Convertible preferred stock, shares authorized	2,100,000	2,100,000
Convertible preferred stock, issued	2,100,000	2,100,000
Convertible preferred stock, outstanding	2,100,000	2,100,000
Convertible preferred stock, redemption value	4,200,000
Convertible preferred stock, liquidation value	4,200,000
Undesignated stock, shares designated	2,100,000
Series C Super Dividend Convertible Preferred Stock
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, issued	220	220
Convertible preferred stock, outstanding	220	220
Convertible preferred stock, redemption value	5,204,000
Convertible preferred stock, liquidation value	$ 2,233,000
Undesignated stock, shares designated	1,000

Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended		150 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Operating expenses:
Research and development	$ 4,527	$ 3,552	$ 27,610
General and administrative	5,372	6,857	47,036
Total operating expenses	9,899	10,409	74,646
Total operating loss	(9,899)	(10,409)	(74,646)
Other income (expense):
Interest income	24	18	818
Interest expense			(4,451)
Change in fair value of convertible debt instrument			(3,426)
Change in fair value of warrant liabilities		(524)	9,022
Other income	200		691
Total other income (expense)	224	(506)	2,654
Net loss	(9,675)	(10,915)	(71,992)
Preferred stock dividends	(976)	(1,568)	(4,235)
Preferred stock accretion	(230)	(230)	(4,045)
Net loss applicable to common stockholders	$ (10,881)	$ (12,713)	$ (80,272)
Basic and diluted net loss per share	$ (0.72)	$ (1.06)
Shares used in computing basic and diluted net loss per share	15,131	11,986

Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (USD $)	Total USD ($)	Issuance During Period 1st USD ($)	Issuance During Period 1st Notes Payable USD ($)	Issuance During Period 1st Convertible Notes Payable USD ($)	Issuance During Period 1st Employee Stock Option USD ($)	Issuance During Period 2nd USD ($)	Issuance During Period 2nd Convertible Notes Payable USD ($)	Issuance During Period 2nd Cash USD ($)	Issuance During Period 2nd Private Placement USD ($)	Issuance During Period 3rd USD ($)	Issuance During Period 3rd Private Placement USD ($)	Issuance During Period 4th Notes Payable USD ($)	Issuance During Period 5th Private Placement USD ($)	Issuance During Period 6th Consulting Services USD ($)	Issuance During Period 7th Accrued Liabilities USD ($)	Issuance During Period 8th Private Placement USD ($)	Issuance During Period 9th Private Placement USD ($)	Issuance During Period 10th Private Placement USD ($)	Issuance During Period 11th Private Placement USD ($)	Issuance During Period 12th Cash USD ($)	Issuance During Period 14th USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 1st Private Placement USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Issuance During Period 3rd USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Period 1 USD ($)	Series C Super Dividend Convertible Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th USD ($)	Series B Preferred Stock USD ($)	Consultant USD ($)	Common Stock USD ($)	Common Stock Issuance During Period 1st	Common Stock Issuance During Period 1st Notes Payable	Common Stock Issuance During Period 1st Employee Stock Option	Common Stock Issuance During Period 2nd USD ($)	Common Stock Issuance During Period 2nd Cash	Common Stock Issuance During Period 3rd USD ($)	Common Stock Issuance During Period 3rd Private Placement USD ($)	Common Stock Issuance During Period 4th Notes Payable	Common Stock Issuance During Period 5th Private Placement	Common Stock Issuance During Period 6th Consulting Services	Common Stock Issuance During Period 7th Accrued Liabilities	Common Stock Issuance During Period 8th Private Placement USD ($)	Common Stock Issuance During Period 9th Private Placement	Common Stock Issuance During Period 10th Private Placement	Common Stock Issuance During Period 11th Private Placement USD ($)	Common Stock Issuance During Period 12th Cash USD ($)	Common Stock Issuance During Period 14th USD ($)	Common Stock Series A 12% Convertible Preferred Stock	Common Stock Series B-1 12% Redeemable Convertible Preferred Stock	Common Stock Series B-2 12% Redeemable Convertible Preferred Stock	Common Stock Series C Super Dividend Convertible Preferred Stock	Common Stock Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th	Common Stock Consultant	Additional Paid-In Capital USD ($)	Additional Paid-In Capital Issuance During Period 1st USD ($)	Additional Paid-In Capital Issuance During Period 1st Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 1st Convertible Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 1st Employee Stock Option USD ($)	Additional Paid-In Capital Issuance During Period 2nd USD ($)	Additional Paid-In Capital Issuance During Period 2nd Convertible Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 2nd Cash USD ($)	Additional Paid-In Capital Issuance During Period 2nd Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 3rd USD ($)	Additional Paid-In Capital Issuance During Period 3rd Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 4th Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 5th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 6th Consulting Services USD ($)	Additional Paid-In Capital Issuance During Period 7th Accrued Liabilities USD ($)	Additional Paid-In Capital Issuance During Period 8th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 9th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 10th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 11th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 12th Cash USD ($)	Additional Paid-In Capital Issuance During Period 14th USD ($)	Additional Paid-In Capital Series A 12% Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Additional Paid-In Capital Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-2 12% Redeemable Convertible Preferred Stock Issuance During Period 3rd USD ($)	Additional Paid-In Capital Series B-2 12% Redeemable Convertible Preferred Stock Period 1 USD ($)	Additional Paid-In Capital Series C Super Dividend Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th USD ($)	Additional Paid-In Capital Consultant USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 1st Private Placement USD ($)	Deficit Accumulated During the Development Stage USD ($)	Deficit Accumulated During the Development Stage Series A 12% Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Deficit Accumulated During the Development Stage Series C Super Dividend Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B Preferred Stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Series B Preferred Stock USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Issuance During Period 3rd USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Period 1 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Series B Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th USD ($)
Beginning Balance at Jul. 10, 2000
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001 (in shares)																																			114,884
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001	$ 2,221,000																																																										$ 2,221,000
Issuance of shares related to reverse split of common stock																																			3,324
Issuance of restricted common stock																																			454,167
Issuance of restricted common stock																																			1,000																								(1,000)
Issuance of common stock upon exercise of warrants																																			3,419,570
Issuance of common stock upon exercise of warrants	14,307,000																																		3,000																								14,304,000
Issuance of common stock upon exercise of options																																						2,772	398,937
Issuance of common stock upon exercise of options					74,000	362,000																																	1,000																								74,000	361,000
Stock-based compensation expense	11,635,000																																																										11,635,000
Net loss	(71,992,000)																																																																																											(71,992,000)
Issuance of founders shares July 10, 2000 (in shares)																																			2,059,112
Issuance of founders shares July 10, 2000	9,000																																		2,000																								7,000
Convertible preferred stock dividend (in shares)																																																					160,330	298,807	568,721	63,119
Convertible preferred stock dividend																						(47,000)									(33,000)																																																	875,000	1,034,000		2,022,000			224,000							(922,000)	(1,034,000)		(2,022,000)			(257,000)
Beneficial conversion feature	222,000																													1,016,000																													222,000																										1,016,000																								(1,016,000)
Issuance of common stock and beneficial conversion feature related to convertible note in 2001 (in shares)																																			110,054
Issuance of common stock and beneficial conversion feature related to convertible note in 2001	1,036,000																																																										1,036,000
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001 (in shares)																																			203,649
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001	107,000																																																										107,000
Issuance of common stock (in shares)																																					99,705			31,000		537,227	17,647	181,334	2,042	33,618	399,917	219,096	206,019	333,334	1,250,000	2,666,722
Issuance of common stock			1,126,000					602,000			2,861,000	290,000	1,070,000	12,000	302,000	4,410,000	1,319,000	1,898,000	490,000	1,044,000	10,403,000																					1,000					1,000			1,000	1,000	3,000									1,126,000					602,000			2,860,000	290,000	1,070,000	12,000	302,000	4,409,000	1,319,000	1,898,000	489,000	1,043,000	10,400,000
Issuance of Common Stock Warrants				503,000			236,000		261,000	20,000																																																				503,000			236,000		261,000	20,000
Receipt of subscription receivable	150,000																																																										150,000
Reclassification of Warrant Liabilities	3,193,000																																																										3,193,000
Deferred compensation relating to issuance of stock options	455,000																																																										455,000
Stock compensation expense related to fair market revaluation	157,000																																																										157,000
Stock compensation related to the issuance of common shares (in shares)																																			12,515
Stock compensation related to the issuance of common shares	53,000																																																										53,000
Cumulative effect of adoption of new accounting principle	(204,000)																																																										(458,000)																																	254,000
Accretion of redeemable convertible preferred stock																								(1,303,000)			(2,057,000)	(685,000)																																																																			(1,303,000)		(2,057,000)	(685,000)				1,303,000				2,057,000	685,000
Issuance of redeemable convertible preferred stock (in shares)																																																																																											1,742,500												900,000					2,100,000					225
Issuance of redeemable convertible preferred stock																							704,000		1,105,000				2,761,000																																																					1,105,000		2,761,000							704,000												395,000					1,174,000					2,203,000
Stock issued in conversion of convertible securities (in shares)																																				79,367			1,227,972		867,558												30,000				8,334																																	(180,000)																							(5)
Stock issued in conversion of convertible securities		1,745,000				3,948,000				5,330,000																						49,000							1,000		1,000																			1,745,000				3,947,000				5,329,000												72,000							49,000			(72,000)																							(49,000)
Ending Balance at Dec. 31, 2012	1,165,000																																		16,000																								80,535,000																														632,000			(80,018,000)									1,698,000										2,154,000
Ending Balance (in shares) at Dec. 31, 2012																																			16,060,853																																																						1,562,500												900,000										220
Beginning Balance at Dec. 31, 2009
Issuance of common stock (in shares)																										770,000
Ending Balance at Dec. 31, 2010	(1,694,000)																																		11,000																								54,075,000																														644,000			(56,424,000)									1,664,000				2,474,000						2,073,000
Ending Balance (in shares) at Dec. 31, 2010																																			10,651,535																																																						1,592,500												900,000				2,100,000						212
Accretion of beneficial conversion feature for Series B-2	(54,000)																																																																																											(54,000)													54,000
Issuance of restricted common stock																																			20,834
Issuance of common stock upon exercise of warrants																																			1,771,383
Issuance of common stock upon exercise of warrants	7,218,000																																		2,000																								7,216,000
Issuance of common stock upon exercise of options	216,443																																		216,440
Issuance of common stock upon exercise of options	234,000																																																										234,000
Stock-based compensation expense	3,245,000																																																										3,245,000
Net loss	(10,915,000)																																																																																											(10,915,000)
Convertible preferred stock dividend (in shares)																																																					30,321	59,588	139,037	17,066
Convertible preferred stock dividend																						1,000									(33,000)																																																	180,000	378,000		881,000			97,000							(179,000)	(378,000)		(881,000)			(130,000)
Issuance of common stock (in shares)																																																																																																																13
Issuance of common stock																																																																																																																130,000
Accretion of redeemable convertible preferred stock																																	(176,000)																																																																			(176,000)				17,000						159,000
Stock issued in conversion of convertible securities (in shares)																																																					5,000			8,334																																		(30,000)																						(5)
Stock issued in conversion of convertible securities																															49,000																																																	12,000						49,000				(12,000)																						(49,000)
Ending Balance at Dec. 31, 2011	(2,125,000)																																		13,000																								66,367,000																														632,000			(69,137,000)									1,681,000				2,687,000						2,154,000
Ending Balance (in shares) at Dec. 31, 2011																																			12,919,538																																																						1,562,500												900,000				2,100,000						220
Accretion of beneficial conversion feature for Series B-2	(56,000)																																																																																											(56,000)													56,000
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001 (in shares)																																			2,666,722
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001	10,403,000																																		3,000																								10,400,000
Issuance of shares related to reverse split of common stock																																			3,324
Issuance of common stock upon exercise of warrants																																			12,177
Issuance of common stock upon exercise of options	51,830																																		51,830
Stock-based compensation expense	2,766,000																																																										2,766,000
Net loss	(9,675,000)																																																																																											(9,675,000)
Convertible preferred stock dividend (in shares)																																																					31,250	95,584	223,027	46,053
Convertible preferred stock dividend																															(123,000)																																																	103,000	224,000		522,000			127,000							(103,000)	(224,000)		(522,000)			(127,000)
Issuance of common stock (in shares)																																																										11,348
Issuance of common stock	68,800,000																																	26,000																																																						26,000
Accretion of redeemable convertible preferred stock																																	(174,000)																																																																			(174,000)				17,000						157,000
Ending Balance at Dec. 31, 2012	$ 1,165,000																																		$ 16,000																								$ 80,535,000																														$ 632,000			$ (80,018,000)									$ 1,698,000				$ 2,900,000						$ 2,154,000
Ending Balance (in shares) at Dec. 31, 2012																																			16,060,853																																																						1,562,500												900,000				2,100,000						220

Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended	150 Months Ended
	Dec. 31, 2012	Dec. 31, 2012
Issuance of stock, issuance costs	$ 1,597,000	$ 17,000
Issuance During Period 14th
Issuance of stock, issuance costs		1,597,000
Series B-1 12% Redeemable Convertible Preferred Stock \| Issuance During Period 2nd
Issuance of stock, issuance costs		300,000
Series B-2 12% Redeemable Convertible Preferred Stock \| Issuance During Period 3rd
Issuance of stock, issuance costs		188,000
Series C Super Dividend Convertible Preferred Stock \| Issuance During Period 4th
Issuance of stock, issuance costs		47,000
Cash \| Issuance During Period 2nd
Issuance of stock, issuance costs		49,000
Cash \| Issuance During Period 12th
Issuance of stock, Date		Feb. 25, 2008
Issuance of stock, issuance costs		369,000
Private Placement \| Issuance During Period 3rd
Issuance of stock, issuance costs		212,000
Private Placement \| Issuance During Period 5th
Issuance of stock, issuance costs		18,000
Private Placement \| Issuance During Period 8th
Issuance of stock, issuance costs		128,000
Private Placement \| Issuance During Period 9th
Issuance of stock, issuance costs		559,000
Private Placement \| Issuance During Period 10th
Issuance of stock, issuance costs		466,000
Private Placement \| Issuance During Period 11th
Issuance of stock, issuance costs		485,000
Private Placement \| Series A 12% Convertible Preferred Stock \| Issuance During Period 1st
Issuance of stock, Date		Feb. 04, 2008
Issuance of stock, issuance costs		$ 52,000

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended		150 Months Ended
Consolidated Statements Of Cash Flows (USD $)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,675,000)	$ (10,915,000)	$ (71,992,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,000	9,000	555,000
Stock-based compensation expense	2,792,000	3,245,000	12,374,000
Non-cash interest expense			4,279,000
Change in fair value of convertible debt instrument			3,426,000
Change in fair value of warrant liabilities		524,000	(9,022,000)
Write off of intangible assets			351,000
Changes in operating assets and liabilities:
Grant receivable		234,000
Prepaid expenses and other assets	(55,000)	(34,000)	(156,000)
Accounts payable and accrued expenses	(577,000)	1,273,000	1,626,000
Other long-term liabilities	6,000	(12,000)	6,000
Net cash used in operating activities	(7,500,000)	(5,676,000)	(58,553,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5,000)	(5,000)	(431,000)
Change in restricted cash and security deposit	69,000	(10,000)
Increase in patents costs and other assets			(404,000)
Net cash provided by (used in) investing activities	64,000	(15,000)	(835,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants	10,403,000		39,093,000
Net proceeds from issuance of convertible debt instruments			10,621,000
Repayment of convertible debt instruments			(1,641,000)
Net proceeds from exercise of common stock warrants and options		6,067,000	11,293,000
Proceeds from shareholder advances			9,000
Net cash provided by financing activities	10,403,000	6,197,000	68,752,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,967,000	506,000	9,364,000
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	6,397,000	5,891,000
CASH AND CASH EQUIVALENTS, END OF PERIOD	9,364,000	6,397,000	9,364,000
SUPPLEMENTAL DISCLOSURE-Cash paid for interest			114,000
NONCASH FINANCING ACTIVITIES:
Issuance of equity warrants in connection with equity offerings	4,445,000		9,482,000
Conversion of accrued expenses into common stock	26,000		329,000
Cashless exercise of stock options and warrants	235,000	341,000	674,000
Conversion and redemptions of convertible notes and accrued interest into common stock			12,243,000
Conversion of extension costs related to convertible notes into common stock			171,000
Payment of preferred stock dividends in common stock	976,000	1,536,000	4,155,000
Issuance of warrants to induce conversion of notes payable			503,000
Issuance of stock to acquire Pro-Pharmaceuticals-NV			107,000
Series A 12% Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible preferred stock and related warrants			1,691,000
Series B-1 12% Redeemable Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of redeemable convertible preferred stock and related warrants			1,548,000
Series B-2 12% Redeemable Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of redeemable convertible preferred stock and related warrants			3,935,000
Series C Super Dividend Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible preferred stock and related warrants		$ 130,000	$ 2,203,000